Hepatitis C Virus Relapse After Ultrashort Direct-Acting Antiviral Therapy Associates With Expression of Genes Involved With Natural Killer-Cell and CD8$^+$ T-Cell Function

Cody Orr,1 Henry Masur,2 Shyam Kottilil,3 and Eric G. Meissner1,4,*

1Division of Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina, USA, 2Critical Care Medicine Department, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA, 3Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA, 4Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA

To identify immunologic correlates of hepatitis C virus (HCV) relapse after direct-acting antiviral (DAA) therapy, we quantified select immune transcripts in whole blood from noncirrhotic HCV subjects treated with 4–6 weeks of DAAs. We identified specific markers of natural killer-cell and CD8$^+$ T-cell function (GZMB, PRF1, NKp46) with higher expression in subjects who relapsed. These findings suggest a role for host immunity in HCV eradication with ultrashort DAA therapy.

Keywords. direct acting antiviral; gene expression analysis; hepatitis C virus; relapse; sustained virologic response.

Most, but not all, chronic hepatitis C virus (HCV) patients treated for 8–12 weeks with direct-acting antivirals (DAAs) achieve a sustained virologic response (SVR), synonymous with cure. Virologic relapse occurs in some patients, but not others, for reasons that are poorly understood and do not always relate to viral resistance or medication adherence [1–3]. The majority of patients treated with DAAs experience rapid downregulation of endogenous interferon (IFN) activity and changes in the distribution and function of innate and adaptive immune cells in liver and peripheral blood [4–8]. Although functional markers on total and antigen-specific CD4$^+$ T lymphocytes, CD8$^+$ T lymphocytes, and natural killer (NK) cells change during DAA therapy, it has not been delineated which changes might affect or reflect the odds of achieving SVR [9–12].

Our prior work identified changes in whole blood that correlated with virologic relapse after HCV treatment with sofosbuvir and ribavirin [13]. In peripheral blood, pretreatment NK-cell concentration, higher pretreatment expression of genes associated with T-cell dysfunction and tolerance, and differential expression of select genes associated with type-I IFN signaling correlated with the odds of virologic relapse [13]. In this current report, we analyzed whole blood from subjects who relapsed after ultrashort treatment with 4–6 weeks of sofosbuvir-based DAA therapy to further explore immune correlates of treatment outcome [2, 14]. Our overarching hypothesis is that peripheral markers of immune function may reflect intrahepatic events that influence relapse risk irrespective of the specific DAA regimen used for treatment. Understanding the correlates of treatment outcome could have significant practical implications for predicting relapse and identifying patients who can benefit from shorter treatment. Given high rates of SVR achieved with currently approved regimens, analysis of samples from ultrashort DAA therapy is an ideal way to assess the contribution of host immunity to HCV treatment outcome.

MATERIALS AND METHODS

Clinical Samples

We used whole blood collected during clinical trials from subjects receiving combination DAA therapy for 4 or 6 weeks and relapsed (n = 33) or achieved SVR (n = 55). In the 4-week clinical trial, subjects had F0-F2 liver fibrosis and received therapy with sofosbuvir and ledipasvir combined with vedroprevir (n = 25) or vedroprevir + radalbuvir (n = 25) [14]. Sofosbuvir (an NS5B inhibitor) and ledipasvir (an NS5A inhibitor) are US Food and Drug Administration-approved medications, whereas vedroprevir (GS-9451) and radalbuvir (GS-9669) are investigational NS3/4A and NS5B inhibitors, respectively. Sustained virologic response was achieved in 10 of 25 subjects treated with 3-drug therapy and 5 of 25 subjects receiving 4-drug therapy [14]. Baseline viral load, genotype 1b infection, age, and presence of resistance variants in the NS3 and NS5 loci associated with odds of virologic relapse, as previously reported [14]. In the 6-week clinical trial, subjects had F0-F3 liver fibrosis and received therapy with sofosbuvir and ledipasvir combined with radalbuvir (n = 20) or vedroprevir (n = 20) [2]. Sustained virologic response was achieved by 19 of 20 subjects in each arm, with 1 relapse occurring in the radalbuvir arm and 1 patient lost to follow up in the vedroprevir arm after having undetectable viral load 4 weeks after treatment (SVR4) [2]. For the purpose of this molecular analysis, the subject lost to follow up was presumed to have achieved SVR.
Paired pre- and posttreatment whole blood collected in PaxGene tubes and stored at −80°C was available from 88 subjects in these trials (Supplemental Table 1). Posttreatment samples were collected immediately after completing treatment and before virologic relapse. Ribonucleic acid (RNA) extraction was performed using the QIAGEN PAXgene Blood miRNA Kit following the manufacturer instructions, as previously described [13]. RNA integrity was determined using an Agilent Bioanalyzer (Genomics Shared Resource, MUSC Hollings Comprehensive Cancer Center) yielding a median RNA integrity number of 8.3 for all samples.

Patient Consent Statement
As previously reported with the initial publication of the clinical trial results [2, 14], all subjects provided written informed consent, which included permission to use samples and data collected in the initial trial for future studies. The current study was approved by the Institutional Review Board at the Medical University of South Carolina.

Gene Quantitation
Direct quantitation of selected transcripts was performed using 100 ng of total RNA on a Nanostring nCounter system using 30 preselected immune markers and 5 housekeeping genes (gene list provided in Supplemental File 1). RCC files were imported into nSolver 4.0 software and analyzed using the default analysis pipeline. Normalization was performed using 6 internal control probes to account for differences between sample cartridges.

RESULTS
We used whole blood collected before and after 4–6 weeks of DAA treatment to identify transcriptional correlates of HCV treatment outcome. We quantitated expression of 30 preselected genes of interest (Supplemental File 1) based on prior work suggesting their potential to correlate with the risk of HCV relapse [13].

Multiple IFN-stimulated genes (ISGs) decreased during treatment, consistent with previous findings (Figure 1) [4–6, 13], whereas type-I and type-III IFN receptor expression did not change. Expression of ISGs and IFN receptors did not differ pre- or posttreatment based on treatment outcome (data not shown). We identified 4 genes that correlated with higher odds of relapse. Subjects who relapsed had higher pretreatment

![Figure 1](https://example.com/fig1.png)

Figure 1. Interferon (IFN)-stimulated gene expression decreases in whole blood during short course direct-acting antiviral therapy, but IFN receptor expression does not. Shown are paired pretreatment (in black) and posttreatment (in blue) expression values for the indicated genes (n = 88 subjects). The * represents genes whose expression changes significantly (P < .05 by paired t test). Individual data points, mean, and standard error are shown. None of these genes had differential expression between sustained virologic response and relapse either pre- or posttreatment.
gene expression of GZMB (granzyme B), PRF1 (perforin), and NKp46 (NCR1), and lower expression of CTLA4 relative to subjects who achieved SVR (Figure 2). In posttreatment whole blood obtained before virologic relapse, relapers continued to have higher expression of GZMB and NKp46, whereas PRF1 and CTLA4 expression were no longer significantly different (Figure 2). Multiple genes that differed in our prior analysis of subjects treated with sofosbuvir and ribavirin did not change over the course of treatment or differ by treatment outcome in this study. These included genes associated with adaptive immune function (CD274/PD1L, HAVCR2/TIM3, IDO1), innate immune signaling (IRAK4, IFNAR1, IFNAR2, SOCS3, TLR8, TOLLIP), and NK-cell function (CD244, KLRC3, KLRC4, KLRD1, KLRG1, KLRK1) (data not shown).

DISCUSSION

Our primary finding is that higher pretreatment expression of GZMB, PRF1, and an activating NK-cell receptor (NCR1/NKp46) associate with higher odds of HCV relapse in subjects treated with ultrashort courses of DAAs for 4–6 weeks. GZMB and NCR1 expression remained higher at the end of treatment in relapers relative to subjects achieving SVR. In a prior study by our group in subjects treated with sofosbuvir and ribavirin for 24 weeks, each of these 3 markers had higher expression posttreatment in relapers [13]. These genes are associated with NK-cell and cytotoxic CD8+ T-cell function, and their consistent association with relapse across multiple DAA studies suggests that viral relapse may have an immunologic basis irrespective of the DAA regimen that is used for treatment. Although ISG expression decreased during treatment in this study (Figure 1), we did not identify a correlation with relapse, which suggests that ISG expression alone is inadequate to explain differential treatment outcome for short-course therapy.

Our findings are consistent with prior work showing restoration of NK-cell subsets and a reduction in exhaustion markers on CD8+ T cells in subjects achieving SVR with different DAA regimens [9, 10, 12]. Our observation of differential NKp46 expression both pre- and posttreatment in relapers is also consistent with prior reports that associated hepatic NKp46 expression and NK-cell activation with treatment outcome after IFN-based therapy [15, 16]. More importantly, cytolysis of HCV-infected hepatocytes is executed by perforin and granzyme B that are secreted by cytotoxic CD8+ T cells and NK cells [17]. The higher expression of GZMB and PRF1 we observed in relapers suggests that a heightened dysfunctional immune response to HCV may mechanistically relate to treatment relapse.

In the initial clinical trial report, higher HCV viral load, younger age, genotype 1b infection, and baseline resistance variants in the NS3 and NS5 region of HCV were associated with relapse [2, 14]. Taken together, these studies suggest immune dysfunction may prevent the hosts’ ability to overcome high viral loads and baseline-resistant variants when therapy is shortened, helping to explain why ultrashort DAA therapy is only effective for a subset of patients. Because longer treatment with DAAs for patients with unfavorable baseline characteristics typically results in SVR, it is thus plausible that DAAs are capable of achieving SVR without significant help from the host immune system when given for longer periods of time. The immune correlates identified in this study may be relevant for understanding the rare instances of relapse that occur with currently approved DAA therapies and may also relate to the risk of reinfection.
limitations of this study include the use of whole blood for gene expression analysis. Although this approach was taken based on the ease of collection and analysis, attribution of gene expression findings to specific cell-types is not possible. Moreover, no individual gene or group of genes examined had enough differential expression by outcome to suggest potential for clinical utility to guide treatment decisions for individual patients. In addition, we did not enumerate specific cellular populations in this study to assess whether differences in NK-cell or CD8+ T-cell abundance either before or after treatment correlated with the observed gene expression patterns, nor did we have the ability to examine functional correlates of the gene expression patterns on immune cells. Most markers we measured that were related to NK-cell function did not change over the course of treatment (see results above), and our prior analysis of samples from a different trial identified no change in NK-cell or CD8+ T-cell frequencies 4–6 weeks after starting DAA therapy [7]. This makes it less likely, but still possible, that differences in the abundance of specific cellular populations might explain the differential transcriptional profiles observed. Finally, because only 8 of 88 subjects analyzed in these trials had IFNL4 TT/TT genotype (rs368234815), we could not examine any association of IFNL4 genotype with the reported findings.

CONCLUSIONS

In conclusion, after ultrashort HCV treatment with DAA therapy for 4–6 weeks, relapse of HCV is associated with expression of genes associated with NK-cell and CD8+ T-cell function in whole blood. This suggests that immune function may be an important determinant of response to short-course DAA therapy, and that pharmacologic augmentation of immune function might enhance the efficacy of less costly, more efficient short courses of HCV therapy.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

Disclaimer. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Financial support. This study was funded by the National Institute of Allergy and Infectious Diseases, Grant K08AI121348 (to E. G. M.) and by NIGMS of the National Institutes of Health under award number P20GM130457 (to E. G. M.). This project was also funded in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E, the National Institute of Allergy and Infectious Diseases, and the NIH Critical Care Medicine Department. This work was also funded in part by the Translational Science Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).

Potential conflicts of interest. E. G. M. has served on an Advisory Board for Theratechnologies, Inc and receives research support from Viiv Healthcare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014; 59:1666–74.
2. Kohli A, Osimani A, Sims Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet 2015; 385:1107–13.
3. Kattakuzhy S, Wilson E, Sidhارthan S, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis 2016; 62:440–7.
4. Meissner EG, Wu D, Osimani A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014; 124:3552–63.
5. Martin B, Hennesee N, Lohmann V, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014; 61:538–43.
6. Amaddeo G, Nguyen CT, Maillé P, et al. Intrahepatic immune changes after hepatitis C virus eradication by direct-acting antiviral therapy. Liver Int 2020; 40:74–82.
7. Meissner EG, Kohli A, Higgins J, et al. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun 2017; 1:586–94.
8. Orr C, Aartun J, Masur H, et al. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat 2019; 26:323–8.
9. Stevenson TJ, Barbouro Y, McMahon BJ, et al. Observed changes in natural killer and T cell phenotypes with evaluation of immune outcome in a longitudinal cohort following sofosbuvir-based therapy for chronic hepatitis C infection. Open Forum Infect Dis 2019; 6:eofz223.
10. Spaan M, van Oord G, Kreeft K, et al. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Infect Dis 2016; 213:216–23.
11. Golden-Mason L, McMahon RH, Kriss MS, et al. Early and late changes in natural killer cells in response to ledipasvir/sofosbuvir treatment. Hepatol Commun 2018; 2:364–75.
12. Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015; 149:190–200.e2.
13. Orr C, Xu W, Masur H, et al. Peripheral blood correlates of virologic relapse after sofosbuvir and ribavirin treatment of genotype-1 HCV infection. BMC Infect Dis 2020; 20:829.
14. Kohli A, Kattakuzhy S, Sidhārthan S, et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. Ann Intern Med 2015; 163:899–907.
15. Pembroke T, Christian A, Jones E, et al. The paradox of NKp46+ natural killer cell function: drivers of severe hepatitis C virus-induced pathology but in vivo resistance to interferon α treatment. Gut 2014; 63:515–24.
16. Ahlenstiel G, Edlich R, Hogdal L, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141:1231–9, e1–2.
17. Chigbu DI, Loonawat R, Sehgal M, et al. Hepatitis C virus infection: host–virus interaction and mechanisms of viral persistence. Cells 2019; 8:376.